

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI267706

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| Hélène M. Faessel | 05/19/2024 |
| RECEIVING PARTY DATA | |
| Company Name: | Takeda Development Center Americas, Inc. |
| Street Address: | 500 Kendall Street |
| City: | Cambridge |
| State/Country: | MASSACHUSETTS |
| Postal Code: | 02142 |
| PROPERTY NUMBERS Total: 4 | |
| Property Type | Number |
| Application Number: | 16369729 |
| Application Number: | 16563161 |
| Application Number: | 17866203 |
| Application Number: | 16998900 |
| CORRESPONDENCE DATA | |
| Fax Number: | 2028427899 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 2028427800 |
| Email: | sdivenere@cooley.com,zIPPatentDocketingMailboxUS@COOLEY.com |
| Correspondent Name: | COOLEY LLP |
| Address Line 1: | 1299 PENNSYLVANIA AVENUE NW, SUITE 700 |
| Address Line 4: | Washington, DISTRICT OF COLUMBIA 20004 |
| ATTORNEY DOCKET NUMBER: | 329454-2000 |
| NAME OF SUBMITTER: | Samantha Cerami |
| SIGNATURE: | Samantha Cerami |
| DATE SIGNED: | 05/31/2024 |
| Total Attachments: 10 | |
| source=Fully Executed Assignment from Faessel to TDCA#page1.tif | |
| source=Fully Executed Assignment from Faessel to TDCA#page2.tif | |
| source=Fully Executed Assignment from Faessel to TDCA#page3.tif | |

source=Fully Executed Assignment from Faessel to TDCA#page4.tif
source=Fully Executed Assignment from Faessel to TDCA#page5.tif
source=Fully Executed Assignment from Faessel to TDCA#page6.tif
source=Fully Executed Assignment from Faessel to TDCA#page7.tif
source=Fully Executed Assignment from Faessel to TDCA#page8.tif
source=Fully Executed Assignment from Faessel to TDCA#page9.tif
source=Fully Executed Assignment from Faessel to TDCA#page10.tif

Attorney Docket No. MYOV-016/01US 329454-2672
MYOV-016/02US 329454-2682
MYOV-016/03US 329454-2725
MYOV-016/04US 329454-2880

ASSIGNMENT

Hélène M. FAESSEL, having mailing address c/o Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02142 (referred to as "Assignor") has made an invention(s) (the "Invention(s)") set forth in Schedule A

- (1) ☐ provisional application
(a) ☐ to be filed herewith; or
(b) ☐ entitled and bearing Application No. , and filed on ;

- (2) ☐ non-provisional application
(a) ☐ to be filed herewith; or
(b) ☐ entitled and bearing Application No. , and filed on ;

—
and/or

- (3) ☐ PCT application
(a) ☐ to be filed herewith; or
(b) ☐ entitled and bearing Application No. , and filed on .

wherein the Schedule A patents and patent application(s) claim(s) priority to:

| Country | Application No. | Application Filing Date |
|--------------------------|-----------------|-------------------------|
| United States of America | 62/402,150 | 9/30/2016 |
| United States of America | 62/402,004 | 9/30/2016 |

WHEREAS, Takeda Development Center Americas, Inc., a Company, having its principal place of business at 500 Kendall Street, Cambridge, MA 02142 (the "Assignee"), its successors, legal representatives, and assigns, is desirous of acquiring the Assignor's entire right, title, and interest in and to the Invention(s); the application(s) for patent and/or registered design identified above; the right to file applications for patent and/or registered design of the United States or other countries on the Invention(s); any application(s) for patent and/or registered design of the United States or other countries claiming priority to,

and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) and/or registered design(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent and/or registered design identified above;
- (c) the right to file applications for patent and/or registered design of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent and/or registered design of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent and/or registered design of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent and/or registered design identified above or any application(s) for patent and/or registered design claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent and/or registered design identified in the preceding paragraphs (b)-(e) and of any and all patent(s) and/or registered design(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) and/or registered design(s) of the United States or other countries that may be granted for or on any application for patent and/or registered design identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s) and/or registered design(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is the sole and lawful owner of the Assignor's entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents. The Assignor also hereby represents that, except for said prior agreement, if applicable, the Assignor has not previously sold, transferred, or encumbered any part of Assignor's right, title, and interest in the Invention(s).

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), said registered design(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor waives all rights to challenge the validity of said invention(s) in the United States and its territorial possessions and in all foreign countries and of all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention(s) by said application or any continuation, continuation-in-part, divisional, renewal, substitute, or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the title, filing date, application number, and/or attorney docket number of the application(s) identified above when known.


The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon, for the use and behalf of the Assignee, its successors, legal representatives, and assigns.

Attorney Docket No. MYOV-016/01US 329454-2672/01US 329454-2672
MYOV-016/02US 329454-2682
MYOV-016/03US 329454-2725
MYOV-016/04US 329454-2880


Assignor(s) and Assignee(s) understand that electronic signatures are acceptable and that, by signing electronically, signatories agree to the use of electronic signatures.

19-MAY-2024
Date


Hélène M. Faessel

Witness:

Signature
Pierre Faessel
Printed Name

19 May 2024
Date


Witness:

Signature
Paulette Faessel
Printed Name

19 May 2024
Date

Attorney Docket No. MYOV-016/01US 329454-2672/01US 329454-2672
MYOV-016/02US 329454-2682
MYOV-016/03US 329454-2725
MYOV-016/04US 329454-2880

For and on behalf of ASSIGNEE:

Date: May 20, 2024

By: 
Name: CONSTANCE YEUNG
Title: IP REGION HEAD
Company: Takeda Development Center Americas, Inc.

By signing, I confirm that I am entitled to sign legally binding acts on behalf of Takeda Development Center Americas, Inc.

My position in Takeda Development Center Americas, Inc. is: IP Region Head


Witness:


Signature

May 20, 2024
Date

Noreen Buckley
Printed Name

Witness:


Signature

May 20, 2024
Date

Tomohiro Maeda
Printed Name

Attorney Docket No. MYOV-016/01US 329454-2672/01US 329454-2672
MYOV-016/02US 329454-2682
MYOV-016/03US 329454-2725
MYOV-016/04US 329454-2880

SCHEDULE A

| Country | Title | Application No | Filing Date | Registration No. | Registration Date |
|------------------------------|---|---------------------|-------------|------------------|-------------------|
| Argentina | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | 20170102716 | 9/29/2017 | | |
| Armenia | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| Australia | TREATMENT OF PROSTATE CANCER | 2017334035 | 9/29/2017 | 2017334035 | 3/9/2023 |
| Australia | TREATMENT OF PROSTATE CANCER | 2023201047 | 9/29/2017 | | |
| Azerbaijan | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| Belarus | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| Brazil | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | BR 11 2019 006228 9 | 9/29/2017 | | |
| Canada | TREATMENT OF PROSTATE CANCER | 3038875 | 9/29/2017 | | |
| China | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | 201780072970.4 | 9/29/2017 | | |
| Eurasian Patent Organization | TREATMENT OF PROSTATE CANCER | 201990843 | 9/29/2017 | 043716 | 6/15/2023 |
| European Patent Office | TREATMENT OF PROSTATE CANCER | 17823017.3 | 9/29/2017 | | |

| Country | Title | Application No | Filing Date | Registration No. | Registration Date |
|---------------------------|---|-------------------|-------------|------------------|-------------------|
| Hong Kong | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | 62020002188 | 9/29/2017 | | |
| Israel | TREATMENT OF PROSTATE CANCER | 265697 | 9/29/2017 | 265697 | 6/2/2023 |
| Israel | TREATMENT OF PROSTATE CANCER | 300071 | 9/29/2017 | | |
| Israel | TREATMENT OF PROSTATE CANCER | 308528 | 9/29/2017 | | |
| Japan | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | 538720/2019 | 9/29/2017 | 7062673 | 4/22/2022 |
| Kazakhstan | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| Kyrgyzstan | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| Mexico | TREATING OF PROSTATE CANCER | MX/A/2019/003733 | 9/29/2017 | 399915 | 2/7/2023 |
| Mexico | TREATING OF PROSTATE CANCER | MX/a/2023/001468 | 9/29/2017 | | |
| New Zealand | TREATMENT OF PROSTATE CANCER | 752918 | 9/29/2017 | 752918 | 1/5/2023 |
| Patent Cooperation Treaty | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | PCT/EP2017/074849 | 9/29/2017 | | |

| Country | Title | Application No | Filing Date | Registration No. | Registration Date |
|--------------------------|---|----------------|-------------|------------------|-------------------|
| Russian Federation | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| South Africa | TREATMENT OF PROSTATE CANCER | 2019/02691 | 9/29/2017 | | |
| Tajikistan | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| Turkmenistan | TREATMENT OF PROSTATE CANCER | | 9/29/2017 | 043716 | 6/15/2023 |
| United States of America | METHODS OF TREATING HORMONE DEPENDENT PROSTATE CANCER | 62/402,004 | 9/30/2016 | | |
| United States of America | FORM S-1 REGISTRATION STATEMENT | 62/402,150 | 9/30/2016 | | |
| United States of America | TREATMENT OF PROSTATE CANCER | 16/369,729 | 3/29/2019 | 10,449,191 | 10/22/2019 |
| United States of America | TREATMENT OF PROSTATE CANCER | 16/563,161 | 9/6/2019 | 10,786,501 | 9/29/2020 |
| United States of America | TREATMENT OF PROSTATE CANCER | 16/998,900 | 8/20/2020 | 11,583,526 | 2/21/2023 |
| United States of America | TREATMENT OF PROSTATE CANCER | 17/866,203 | 7/15/2022 | | |